CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-07-11). The draft was written by AI, the existence of all 3 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 280 · Search date 2026-07-11 · Methodology v0.6

NADH,
does it really help with Improved chronic fatigue?

30-Second Summary
C
Evidence Grade C · 42 · Safety acceptable
Monotherapy results conflict, and combination trials cannot isolate the effect of NADH
What the
research shows
A small crossover trial reported more responders, but a larger monotherapy RCT found no difference in most fatigue, function, and quality-of-life outcomes. Positive CoQ10 combination trials cannot isolate NADH, resulting in a C grade.
What the
ads claim
Advertisements directly convert cellular-energy and ATP mechanisms into claims of chronic-fatigue improvement, while monotherapy clinical results are mixed.
*

Useful facts when choosing a product

  • Monotherapy trials used 10-20 mg/day.
  • Positive later trials mainly used CoQ10 200 mg plus NADH 20 mg.
  • Short-term tolerability was generally acceptable in studies.
Gap Measurement · Verdict 280 · C 42
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

In Forsyth 1999, 31% of 26 participants responded to NADH versus 8% to placebo. Alegre 2010 enrolled 86 participants and found no difference in most fatigue, function, and quality-of-life measures apart from selected changes in anxiety and maximum heart rate. Castro-Marrero 2015 reported reduced fatigue with CoQ10 200 mg plus NADH 20 mg in 73 participants.

02

Why this is classified as C (42)

Monotherapy RCTs exist, but a small positive study conflicts with a larger negative study and combination evidence cannot be attributed to NADH, resulting in C with 43 points.

Counterpoint. Signals in selected responders and combination groups remain.

Rejudgment record. New verdict — Small positive monotherapy RCT conflicts with a larger negative monotherapy RCT; positive combination evidence cannot isolate the ingredient

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Forsyth LM et al. 1999Randomized double-blind placebo-controlled crossover trial26Included formulation developer; details unknownComposite responder assessmentResponse was 31% with NADH and 8% with placebo.Positive, small
Alegre J et al. 2010Randomized double-blind placebo-controlled trial77Non-U.S. public research supportFatigue, function, mood, quality of life, and exercise capacityMost clinical variables and global function did not differ, apart from anxiety and maximum heart rate.Key, negative
Castro-Marrero J et al. 2015Randomized double-blind placebo-controlled combination trial73Public and foundation support; supplement combinationFatigue and cellular biochemical markersFatigue and selected biochemical measures improved with CoQ10 plus NADH.Indirect, combination
§

Receipt — 3 References

All 3 cited sources were verified for existence at the original page (as of 2026-07-11).

Forsyth LM, Preuss HG, MacDowell AL, Chiazze L Jr, Birkmayer GD, Bellanti JA. Therapeutic effects of oral NADH on the symptoms of patients with chronic fatigue syndrome. Ann Allergy Asthma Immunol. 1999;82(2):185-191. PMID: 10071523. DOI: 10.1016/S1081-1206(10)62595-1.
checked
Alegre J, Rosés JM, Javierre C, Ruiz-Baqués A, Segundo MJ, Fernández de Sevilla T. Nicotinamide adenine dinucleotide (NADH) in patients with chronic fatigue syndrome. Rev Clin Esp. 2010;210(6):284-288. PMID: 20447621. DOI: 10.1016/j.rce.2009.09.015.
checked
Castro-Marrero J, Cordero MD, Segundo MJ, et al. Does oral coenzyme Q10 plus NADH supplementation improve fatigue and biochemical parameters in chronic fatigue syndrome? Antioxid Redox Signal. 2015;22(8):679-685. PMID: 25386668. DOI: 10.1089/ars.2014.6181.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-11 · Corrections: none

Cite this verdict

NADH (nicotinamide adenine dinucleotide hydride) x improved chronic fatigue Evidence Grade C card
[Chamgap] NADH (nicotinamide adenine dinucleotide hydride) x improved chronic fatigue — Evidence Grade C·42. 3 cited sources checked. Source: https://health-receipt.pages.dev/en/verdicts/energy/nadh-chronic-fatigue/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.